Unique ID issued by UMIN | UMIN000042490 |
---|---|
Receipt number | R000048502 |
Scientific Title | Multi-center clinical trial for personalized perioperative chemotherapy based on genetic alteration status for resectable oligometastases from colorectal cancer |
Date of disclosure of the study information | 2020/11/18 |
Last modified on | 2022/05/22 05:35:37 |
Clinical trial of personalized therapy based on genetic alteration for patients with resectable colorectal oligometastases
Personalized therapy for resectable colorectal oligometastases
Multi-center clinical trial for personalized perioperative chemotherapy based on genetic alteration status for resectable oligometastases from colorectal cancer
PRECISION Study
Japan |
Colorectal oligometastases
Gastrointestinal surgery | Hepato-biliary-pancreatic surgery | Chest surgery |
Malignancy
YES
To prospectively analyze the survival impact of pre-treatment ctDNA analysis on resectable colorectal oligometastases
Others
To investigate the proof of concept of pre-treatment ctDNA analysis for personalized perioperative chemotherapy of resectable colorectal oligometastases
Exploratory
Explanatory
Not applicable
Proportion of BRAF V600E mutation and pre-treatment ctDNA detection in patients with resectable colorectal oligometastases
Survival outcomes depending on status of BRAF V600E mutation and pre-treatment ctDNA detection. Genetic alteration profiles according to ctDNA analysis.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1. Above 20 years of age
2. Written informed consent
3. Colorectal cancer origin
4. Resectable oligometastases
5. Initial surgery is planed.
6. R0/1 resection is possible.
7. ECOG PS 0/1
In G360 cohort, in which pre-treatment ctDNA is analyzed, below criteria are also added.
1. Pathologically-proven adnocarcinoma
2. No prior treatment for oligometastases
3. Written consent for blood test
1. Concomittant unresectable advanced tumor
2. Prior surgery for oligometastases
3. Unresectable unless the tumor is shrinked by preoperative chemotherapy
4. Physician`s judgement for exclusion
In G360 cohort, below criteria are also added.
1. Concomittant tumor that is disease-free within 5 years
2. Pathological diagnosis other than adenocarcinoma
3. Any prior treatment for oligometastases
400
1st name | Shin |
Middle name | |
Last name | Kobayashi |
National Cancer Center Hospital East, Japan
Department of Hepatobiliary and Pancreatic Surgery
277-0882
6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan, 2770882
04-7133-1111
shkobaya@east.ncc.go.jp
1st name | Shin |
Middle name | |
Last name | Kobayashi |
National Cancer Center Hospital East, Japan
Department of Hepatobiliary and Pancreatic Surgery
277-0882
6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan, 2770882
04-7133-1111
shkobaya@east.ncc.go.jp
National Cancer Center Hospital East, Japan
Japan Agency for Medical Research and Development
Japanese Governmental office
National Cancer Center Hospital East, Japan
6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan, 2770882
04-7133-1111
shkobaya@east.ncc.go.jp
NO
2020 | Year | 11 | Month | 18 | Day |
Unpublished
Open public recruiting
2020 | Year | 12 | Month | 01 | Day |
2021 | Year | 03 | Month | 01 | Day |
2021 | Year | 03 | Month | 22 | Day |
2028 | Year | 03 | Month | 31 | Day |
None
2020 | Year | 11 | Month | 18 | Day |
2022 | Year | 05 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048502
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |